2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET | Phase 1 | Terminated | Debiopharm International SA | 19 | 2022-05-18 | 2025-11-17 |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers ONO-5788, ONO-5788 Placebo, Octreotide - Acromegaly | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 76 | 2018-06-07 | 2019-06-05 |
Acromegaly (2) · Gastro-enteropancreatic neuroendocrine tumor (1)
Bone Diseases (2) · Bone Diseases, Endocrine (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Hypothalamic Diseases (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Pituitary Diseases (2)
Octreotide (2) · lanreotide (1)
Debiopharm International SA (1) · Ono Pharmaceutical Co., Ltd. (1)
Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1) · United States (1)